Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
1.950
0.00 (0.00%)
Jan 22, 2025, 3:54 PM EST - Market closed
Harvard Bioscience Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Harvard Bioscience.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for HBIO.
Recommendation Trends
Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 2 | 2 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 2 | 3 | 3 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Benchmark | Benchmark | Buy Reiterates $7 | Buy | Reiterates | $7 | +258.97% | Jun 22, 2023 |
Benchmark | Benchmark | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +258.97% | Apr 26, 2023 |
Keybanc | Keybanc | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +258.97% | Apr 26, 2023 |
Benchmark | Benchmark | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +105.13% | Mar 10, 2023 |
Keybanc | Keybanc | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +156.41% | Nov 9, 2022 |
Financial Forecast
Revenue This Year
95.63M
from 112.25M
Decreased by -14.81%
Revenue Next Year
99.76M
from 95.63M
Increased by 4.32%
EPS This Year
n/a
from -0.08
EPS Next Year
0.13
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | 99.9M | 103.7M | 117.6M |
Avg | 95.6M | 99.8M | 114.2M |
Low | 90.6M | 94.9M | 109.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | -11.0% | 8.5% | 17.9% |
Avg | -14.8% | 4.3% | 14.5% |
Low | -19.3% | -0.8% | 10.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | 0.19 | 0.26 |
Avg | - | 0.13 | 0.26 |
Low | - | 0.07 | 0.25 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | 105.9% |
Avg | - | - | 100.0% |
Low | - | - | 92.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.